The Technical AnalystExchange: STO Sector: Healthcare Industry: Biotechnology
2cureX AB (publ) Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.28% SEK0.352
America/New_York / 17 mai 2024 @ 05:10
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 6.20 mill |
| EPS: | -1.870 |
| P/E: | -0.190 |
| Earnings Date: | Feb 22, 2024 |
| SharesOutstanding: | 17.60 mill |
| Avg Daily Volume: | 0.0902 mill |
| RATING 2024-05-17 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Sell | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | |||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.190 | sector: PE 19.76 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -0.190 | industry: PE 491.84 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
SEK0.667 (89.59%) SEK0.315 |
| Date: 2024-05-18 |
| Expected Trading Range (DAY) |
|---|
|
SEK 0.243 - 0.461 ( +/- 30.97%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | SEK0.352 (0.28% ) |
| Volume | 0.0004 mill |
| Avg. Vol. | 0.0902 mill |
| % of Avg. Vol | 0.388 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For 2CUREX.ST
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
2CUREX.ST
2cureX AB (publ) operates as a medtech company in Europe. Its principal product is IndiTreat, an IVD test, which helps to predict cancer patient's response and resistance to different drugs and select the appropriate treatment. The company is also conducting various clinical programs for IndiTreat for breast colorectal, ovarian, and pancreatic cancers. 2cureX AB (publ) was incorporated in 2006 and is based in Copenhagen, Denmark.